Highlights of This Issue 6645

SPECIAL FEATURES

CCR Translations

6647 The Context of Blood Vessels and Response to VEGF-Targeted Therapy
Brian I. Rini
See related article, p. 6943

CCR Perspectives in Drug Approval

6650 Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

CCR Drug Updates

6657 Pralatrexate Pharmacology and Clinical Development
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O’Connor

Molecular Pathways

6662 Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
Lorena Fontán and Ari Melnick

Perspectives

6669 Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?
Anita Sveen, Arild Neskabken, Knud H. Agersen, Marianne G. Guren, Kjell M. Tvet, Rolf L Skotheim, and Ragnhild A. Lothe

Review

6678 Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

HUMAN CANCER BIOLOGY

6686 Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeças, Maria Calaminici, and John G. Grihben

6696 BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

6703 HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaoije Meng, Rachel Thompson, Xinboao Hao, Yongmin Li, Xiaotan T. Qiao, Jianyu Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

CANCER THERAPY: PRECLINICAL

6716 Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagiymbek Manap, Lirinl Xia, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Rausan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Klein, Werner Scheurer, Romi Raemisch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarello, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas

Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response

Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milesevic, Bradly G. Wouters, Robert G. Bristow, and Marianne Koritzinsky

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loreta Pia Ciaffreda, Sara Costantino, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nanni, Raffaele De Palma, Elena D’Aiuto, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello

Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors

Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock

The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

Jih-Hsiang Lee, Kang-Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng-Tzu Weng, Yisong Wang, and Giuseppe Giaccone

A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

Isabel Puig, Irene Chicote, Stephen P. Tenbaum, Oriol Arqués, José Raúl Herance, Juan D. Gispert, José Jimenez, Stefania Landolfo, Karina Caci, Helena Allende, Leire Mendizábal, Débora Moreno, Ramón Charco, Eloy Espín, Alexis Prat, Maria Elena Elez, Guillem Argilés, Ana Vivancos, Josep Tabernero, Santiago Rojas, and Héctor G. Palmer

Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing P13K/AKT Signaling, Tumor Growth, and Metastasis

Ren Liu, Xiaoping Li, Wenming Guo, Yue Zhou, Shuan Wey, Santajit K. Mitra, Valery Krasnoperov, Dezhang Dong, Shuanglong Liu, Dan Li, Genyuang Zhu, Stan Louie, Peter S. Conti, Zibo Li, Amy S. Lee, and Parkash S. Gill

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma


A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma

Arutselvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas


Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma


IMAGING, DIAGNOSIS, PROGNOSIS

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas


Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6853</td>
<td>The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy</td>
<td>Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao</td>
</tr>
<tr>
<td>6863</td>
<td>Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis</td>
<td>Carlo Palmieri, John R. Fullarton, and Janet Brown</td>
</tr>
<tr>
<td>6873</td>
<td>Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia</td>
<td>Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Ralfeld, and Maryalice Stetler-Stevenson</td>
</tr>
<tr>
<td>6882</td>
<td>Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma</td>
<td>Yasuhito Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jieixin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes</td>
</tr>
<tr>
<td>6912</td>
<td>Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors</td>
<td>David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Yauch, Thomas O’Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont</td>
</tr>
<tr>
<td>6924</td>
<td>The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer</td>
<td>Kevin Sharpe, Grant D. Stewart, Alan Mackay, Christophe Van Neste, Charlotte Rofe, Dan Berney, Irfan Kayani, Axel Bex, Elaine Wan, Fiach C. O'Mahony, Marie O'Donnell, Simon Chowdhury, Rukma Doshi, Colan Ho-Yen, Marco Gerlinger, Dawn Baker, Neil Smith, Barry Davies, Anju Sahdev, Ekaterini Boleti, Tim De Meyer, Wim Van Crieckinge, Luis Beltran, Yong-Jie Lu, David J. Harrison, Andrew R. Reynolds, and Tom Powles</td>
</tr>
<tr>
<td>6935</td>
<td>Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib</td>
<td>Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xian Sheng, Li Xin, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo</td>
</tr>
<tr>
<td>6957</td>
<td>Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)</td>
<td>Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedv L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials In Oncology</td>
</tr>
</tbody>
</table>
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial


Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andres Cervantes, Josep Tabernero, Premal Patel, and Jose Baselga

Acknowledgment to Reviewers

ABOUT THE COVER

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.